BSE Live
Apr 21, 16:01Prev. Close
78.47
Open Price
77.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 21, 15:55Prev. Close
77.69
Open Price
77.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Bal Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 303.08 | 326.35 | 304.22 | 279.70 | 246.94 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 303.08 | 326.35 | 304.22 | 279.70 | 246.94 | |
| Total Operating Revenues | 303.08 | 339.22 | 304.22 | 281.21 | 250.53 | |
| Other Income | 2.20 | 2.85 | 0.94 | 5.15 | 1.14 | |
| Total Revenue | 305.29 | 342.07 | 305.16 | 286.37 | 251.67 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 149.89 | 181.58 | 179.19 | 163.99 | 135.47 | |
| Purchase Of Stock-In Trade | 15.06 | 11.24 | 11.45 | 8.43 | 10.43 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -7.05 | -1.06 | -17.87 | -4.89 | 5.05 | |
| Employee Benefit Expenses | 62.40 | 60.38 | 55.30 | 47.25 | 41.88 | |
| Finance Costs | 16.85 | 15.26 | 12.19 | 10.41 | 11.97 | |
| Depreciation And Amortisation Expenses | 9.77 | 10.07 | 9.13 | 9.04 | 9.52 | |
| Other Expenses | 53.23 | 55.56 | 51.03 | 42.96 | 33.25 | |
| Total Expenses | 300.15 | 333.02 | 300.41 | 277.18 | 247.56 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 5.14 | 9.05 | 4.75 | 9.18 | 4.10 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 5.14 | 9.05 | 4.75 | 9.18 | 4.10 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 3.20 | 2.58 | 4.48 | 0.38 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.96 | 0.85 | 0.10 | -1.94 | -0.99 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | -2.10 | 1.60 | 2.13 | 3.48 | -0.61 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 7.24 | 7.45 | 2.62 | 5.70 | 4.71 | |
| Profit/Loss From Continuing Operations | 7.24 | 7.45 | 2.62 | 5.70 | 4.71 | |
| Profit/Loss For The Period | 7.24 | 7.45 | 2.62 | 5.70 | 4.71 | |
| Minority Interest | -0.02 | -0.05 | -0.05 | -0.09 | 0.03 | |
| Consolidated Profit/Loss After MI And Associates | 7.22 | 7.39 | 2.57 | 5.61 | 4.74 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | |
| Diluted EPS (Rs.) | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 1.91 | 1.57 | 1.56 | 1.48 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
19.11.2025
Bal Pharma Consolidated September 2025 Net Sales at Rs 74.02 crore, up 0.45% Y-o-Y
13.11.2025
Bal Pharma Standalone September 2025 Net Sales at Rs 73.75 crore, down 1.27% Y-o-Y
09.09.2025
Bal Pharma Standalone June 2025 Net Sales at Rs 65.64 crore, down 10.25% Y-o-Y
10.06.2025
Bal Pharma Standalone March 2025 Net Sales at Rs 81.78 crore, down 13.53% Y-o-Y
19.11.2025
Bal Pharma Consolidated September 2025 Net Sales at Rs 74.02 crore, up 0.45% Y-o-Y
13.11.2025
Bal Pharma Standalone September 2025 Net Sales at Rs 73.75 crore, down 1.27% Y-o-Y
09.09.2025
Bal Pharma Standalone June 2025 Net Sales at Rs 65.64 crore, down 10.25% Y-o-Y
10.06.2025
Bal Pharma Standalone March 2025 Net Sales at Rs 81.78 crore, down 13.53% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth